A phase 2 dose escalation trial of carfilzomib in combination with thalidomide and dexamethasone for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma

111 Transplant-eligible patients with newly diagnosed multiple myeloma (aged 18 to 65 years)

- **Induction therapy**: 4 cycles of Carfilzomib, Thalidomide and Dexamethasone (KTd)

Carfilzomib

Dose level			
1 (n=50)	20 mg/m²	27 mg/m²	27 mg/m²
2 (n=20)	20 mg/m²	36 mg/m²	36 mg/m²
3 (n=21)	20 mg/m²	45 mg/m²	45 mg/m²
4 (n=20)	20 mg/m²	56 mg/m²	56 mg/m²



- **High-dose Melphalan (HDM, 200mg/m²) and autologous stem cell trasplantation**
- **Consolidation therapy**: same schedule and dose as induction treatment except for Thalidomide dose (50 mg)

Median follow-up **58.7 months (range 25.1-88.0)**

Efficacy

	After induction therapy	After consolidation therapy
• **Complete response**	18%	63%
• **Very good partial response rate**	65%	86%

	Months	95% CI
• **Median PFS**	58	45-67
• **Median OS**	83	83-not reached

Safety

- **Grade 3/4 adverse events** infections: 11%; respiratory disorders: 8%; skin disorders: 9%; vascular disorders: 9%

Wester *et al.*, Haematologica, 2019